News articles about Ophthotech (NASDAQ:OPHT) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ophthotech earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.900579098374 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news stories that may have impacted Accern Sentiment’s rankings:

Several equities research analysts have issued reports on OPHT shares. Zacks Investment Research raised Ophthotech from a “hold” rating to a “strong-buy” rating and set a $3.25 price target for the company in a report on Monday, November 13th. Stifel Nicolaus reaffirmed a “hold” rating and set a $4.00 price target on shares of Ophthotech in a report on Thursday, September 21st. TheStreet raised Ophthotech from an “e+” rating to a “c” rating in a report on Thursday, November 30th. Finally, ValuEngine raised Ophthotech from a “hold” rating to a “buy” rating in a report on Monday, October 2nd.

Shares of Ophthotech (NASDAQ:OPHT) opened at $3.04 on Tuesday. Ophthotech has a twelve month low of $2.24 and a twelve month high of $5.25. The firm has a market capitalization of $109.56, a price-to-earnings ratio of 1.95 and a beta of 1.58.

In other news, insider David R. Guyer sold 16,520 shares of Ophthotech stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $3.19, for a total transaction of $52,698.80. Following the completion of the sale, the insider now owns 50,494 shares of the company’s stock, valued at $161,075.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Glenn Sblendorio sold 8,089 shares of Ophthotech stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $3.19, for a total value of $25,803.91. Following the sale, the chief executive officer now directly owns 44,584 shares of the company’s stock, valued at approximately $142,222.96. The disclosure for this sale can be found here. Insiders have sold 34,971 shares of company stock valued at $111,481 in the last three months. Insiders own 2.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Ophthotech (OPHT) Given Daily News Sentiment Rating of 0.08” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/ophthotech-opht-given-daily-news-sentiment-rating-of-0-08/1799654.html.

Ophthotech Company Profile

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.

Insider Buying and Selling by Quarter for Ophthotech (NASDAQ:OPHT)

Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.